News

BlogsPosts
Press Release
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in
BlogsPosts
Press Release
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria
BlogsPosts
Press Release
RepliCel Life Sciences Appoints New Chief Financial Officer
VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:
BlogsPosts
Press Release
RepliCel CEO Provides Updated Outlook
Partnership and Investment Fuel Plans for Upcoming Advancements VANCOUVER, Oct. 15, 2018
BlogsPosts
Press Release
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
  YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater China
BlogsPosts
Press Release
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
YOFOTO (China) Health and RepliCel Life Sciences now cleared to close
BlogsPosts
Press Release
RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with
BlogsPosts
Press Release
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
A revised binding term sheet reflects improved terms and positions the parties for closing the
BlogsPosts
Press Release
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for
BlogsPosts
Press Release
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater
BlogsPosts
Press Release
RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy
BlogsPosts
Press Release
RepliCel’s Partnership Initiatives Mature into Licensing Negotiations
Due diligence and confidential discussions now moving into negotiations for products in both the tendon
BlogsPosts
Press Release
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER,
BlogsPosts
Press Release
RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program
Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial VANCOUVER,
BlogsPosts
Press Release
Prominent Skin Aging Researcher Provides Insights into RepliCel’s Clinical Data
“We believe that this novel therapy has the potential to rejuvenate skin in a way
BlogsPosts
Press Release
RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Data from this project expected to take RepliCel’s products to next level of potential commercial
BlogsPosts
Press Release
RepliCel CEO Provides Company Outlook
A data-rich 2017 positions RepliCel for maturity through the next phase of its product development,
BlogsPosts
Press Release
United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to
BlogsPosts
Press Release
Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date
Interim trial results lead researchers to conclude that the injection of RCS-01 is not only
BlogsPosts
Press Release
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.